presented in a standardized order with minimum standards for type size and other graphical features. Therefore, OTC sunscreen products already on the market at that time incurred a one-time burden to comply with the requirements in § 201.66(c) and (d). In the 60-day notice, the burden was estimated as 43,200 hours for existing sunscreen SKUs and 720 hours for new sunscreen SKUs.

The compliance dates for the 2011 sunscreen final rule that lifted the delay of the § 201.66 labeling implementation data for OTC sunscreen products were December 17, 2012, for sunscreen products with annual sales of $25,000 or more and December 17, 2013, for sunscreen products with annual sales of less than $25,000, respectively, when we published the 2012 extension date notice. All currently marketed sunscreen products are, therefore, already required to comply with the Drug Facts labeling requirements in § 201.66 and will incur no further burden in the 1999 Drug Facts labeling final rule. However, new OTC sunscreen drug products will be subject to a one-time burden to comply with Drug Facts labeling requirements in § 201.66. In the 2011 60-day notice, we estimated that as many as 60 new product SKUs marketed each year must comply with Drug Facts regulations. We estimated that these 60 SKUs would be marketed by 30 manufacturers, which will spend approximately 12 hours on each label based on the most recent estimate used for other OTC drug products to comply with the 1999 Drug Facts labeling final rule, including public comments received on this estimate in 2010 that addressed sunscreens. This is equal to 720 hours annually (60 SKUs, 12 hours per SKU). We stated that we do not expect any OTC sunscreens to apply for exemptions or deferrals of the Drug Facts regulations in § 201.66(e). However, we considered this in 2013 and estimated the burden for an exemption or deferral by considering the number of exemptions or deferrals we have received since publication of the 1999 Drug Facts labeling final rule (one response) and estimating that a request for deferral or exemption would require 24 hours to complete. Multiplying the annual frequency of response (0.125) by the number of hours per response (24) gives a total response time for requesting an exemption or deferral equal to 3 hours.

In the Federal Register of August 22, 2018 (83 FR 42509), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

We estimate the burden of this collection of information as follows:

### Table 1—Estimated Annual Third-Party Disclosure Burden

<table>
<thead>
<tr>
<th>Activity</th>
<th>Number of respondents</th>
<th>Number of disclosures per respondent</th>
<th>Total annual disclosures</th>
<th>Average burden per disclosure</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conduct SPF testing in accordance with § 201.327(i) for new sunscreens.</td>
<td>20</td>
<td>1.95</td>
<td>39</td>
<td>24 (30 minutes)</td>
<td>936</td>
</tr>
<tr>
<td>Create PDP labeling in accordance with § 201.327(a)(1) for new sunscreen SKUs.</td>
<td>20</td>
<td>3</td>
<td>60</td>
<td>0.5 (30 minutes)</td>
<td>30</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>966</td>
</tr>
</tbody>
</table>

1 There are no capital costs or operating and maintenance costs associated with this collection of information.

### Table 2—Estimated Annual Third-Party Disclosure Burden

<table>
<thead>
<tr>
<th>Activity</th>
<th>Number of respondents</th>
<th>Number of disclosures per respondent</th>
<th>Total annual disclosures</th>
<th>Average burden per disclosure</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Format labeling in accordance with § 201.66(c) and (d) for new sunscreen SKUs. Request for Drug Facts exemption or deferral § 201.66(e).</td>
<td>20</td>
<td>3</td>
<td>60</td>
<td>12</td>
<td>720</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>723</td>
</tr>
</tbody>
</table>

1 There are no capital costs or operating and maintenance costs associated with this collection of information.

We note that these estimates may be adjusted in the future as the result of a detailed analysis of sunscreen market data conducted by FDA as part of the development of an upcoming proposed rule on OTC sunscreen products (RIN 0910–AA01). FDA intends to either or both amend this information collection or seek approval of additional information collections, as appropriate, concurrent with publication of the proposed rule.


Lowell J. Schiller,
Acting Associate Commissioner for Policy.

[FR Doc. 2019–01529 Filed 2–7–19; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Pilot Project Program Under the Drug Supply Chain Security Act; Program Announcement

AGENCY: Food and Drug Administration, HHS.
I. Background

On November 27, 2013, the Drug Supply Chain Security Act (DSCSA) (Title II of Pub. L. 113–54) was signed into law. The DSCSA outlines critical steps to build an electronic, interoperable system by November 27, 2023, that will identify and trace certain prescription drugs as they are distributed within the United States. Section 202 of the DSCSA added sections 581 and 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360ccc and 360ee–1, respectively). Under section 582(j) of the FD&C Act, FDA is required to establish one or more pilot projects, in coordination with authorized manufacturers, repackers, wholesale distributors, and dispensers, to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain.

FDA is establishing the DSCSA Pilot Project Program to implement section 582(j) of the FD&C Act. This program is intended to assist FDA and members of the pharmaceutical distribution supply chain in the development of the electronic, interoperable system that will identify and trace certain prescription drugs as they are distributed within the United States. Under this program, FDA will work with stakeholders to establish one or more pilot projects to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain. Participation in the DSCSA Pilot Project Program is voluntary and will be open to pharmaceutical distribution supply chain members to apply to the program. FDA will ensure that participation reflects the diversity of the supply chain, including large and small entities from all industry sectors. This notice establishes the DSCSA Pilot Project Program and includes instructions for submitting a request to participate and expectations for program participants.

DATES: FDA will be accepting applications for participation in the DSCSA Pilot Project Program beginning February 8, 2019 and continuing through March 11, 2019. The duration of the DSCSA Pilot Project Program will depend on the pilot project(s) accepted into the program and when the projects are completed.

FOR FURTHER INFORMATION CONTACT: Daniel Bellingham, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–3130, DSCSApilotprojects@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

II. The DSCSA Pilot Project Program

FDA is seeking pilot project participants from the pharmaceutical distribution supply chain (e.g., authorized manufacturers, repackers, wholesale distributors, and dispensers) and other stakeholders. FDA expects potential participants to propose their design and execution of their pilot project in their submission to FDA; however, FDA intends to meet with selected pilot project participants to ensure that the learnings from the pilot project(s) will be complementary in informing all stakeholders in the development of the electronic, interoperable system that will go into effect in 2023. FDA encourages potential participants to focus their proposed pilot project(s) on the DSCSA requirements related to the interoperable, electronic tracing of products at the package level. Specifically, the pilot project(s) should focus on the enhanced requirements for package-level tracing and verification that go into effect in 2023. Such pilot projects will likely be more useful than pilot projects dedicated to lot-level tracing. If there is an adequate number of pilot project submissions, FDA may establish more than one pilot project to accomplish the goals of the DSCSA Pilot Project Program.

A. Products Eligibility

Pilot projects should focus on applicable requirements to any prescription drug that is a “product” within the meaning of section 581(13) of the FD&C Act. FDA anticipates that packages and homogenous cases of product that are part of a pilot project will generally bear a “product identifier” as described in sections 581(14) and 582(a)(9) of the FD&C Act. FDA may also consider proposed pilot projects involving product that may be subject to a waiver, exception or exemption of certain DSCSA requirements, products that are grandfathered, in addition to products that are outside the scope of section 581(13) of the FD&C Act (e.g., over-the-counter medicines) if such project(s) could further the objectives of the DSCSA Pilot Project Program.

B. Potential Issues To Examine and Evaluation Methods To Use in Pilot Projects

On April 5–6, 2016, FDA held a public workshop entitled “Proposed Pilot Project(s) Under the Drug Supply Chain Security Act (DSCSA).” This public workshop provided a forum for members of the pharmaceutical distribution supply chain to discuss the design objectives of pilot projects established by FDA under section 582(j) of the FD&C Act. Based on the information gathered at that workshop and from the comments submitted to the public docket for the workshop (Docket No. FDA–2016–N–0407), FDA identified several potential issues to examine, and evaluation methods to use, in pilot projects established under the DSCSA Pilot Project Program. These potential
issues and evaluation methods are summarized in Table 1. This table is intended only to assist in the design of potential pilot projects; it does not represent FDA’s views or policies regarding the issues described in the table. For ease of reference, the potential issues to examine and evaluation methods have been grouped by focus areas for the pilot projects.

### Table 1—Potential Issues to Examine and Evaluation Methods to Use in Pilot Projects

<table>
<thead>
<tr>
<th>Pilot project focus area</th>
<th>Potential issues to examine</th>
<th>Potential evaluation methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Identifier</strong></td>
<td>• Processes related to the requirement for manufacturers to affix or imprint a product identifier to each package and homogenous case of product intended to be introduced in a transaction into commerce.</td>
<td>• Impacts of different representations of the product identifier on systems or processes: —Number of errors. —Time to process. —Time to reconcile differences.</td>
</tr>
<tr>
<td></td>
<td>• Methods used to issue and manage serial numbers (e.g., including a contract manufacturer’s role if applicable or how a repackager associates its product identifier with the product identifier assigned by the original manufacturer).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Different representations for the product identifier (e.g., different formats of the National Drug Code or serial number).</td>
<td></td>
</tr>
<tr>
<td><strong>Barcodes</strong></td>
<td>• Readability of a barcode either printed or affixed to product, including impact of environmental and human factors.</td>
<td>• Barcode read error rates: —Number of items unnecessarily quarantined or held up. —Time and resource impacts.</td>
</tr>
<tr>
<td></td>
<td>• Application of linear barcode and 2D barcode on product.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Distinguishing which barcode to read/use.</td>
<td></td>
</tr>
<tr>
<td><strong>Interoperability</strong></td>
<td>• Process and technical challenges due to a variety of potential solutions (e.g., type of database used and system architecture for exchanging information among trading partners).</td>
<td>• For both decentralized and centralized models, time implications: —To investigate suspect and illegitimate products. —For notifications required within the statutory timelines. —Related to scaling up from pilot to full production.</td>
</tr>
<tr>
<td></td>
<td>• Maintaining the integrity of information contained in the barcode of serialized product throughout the distribution supply chain (e.g., a trading partner goes out of business or one acquires another business).</td>
<td>• Product tracing information (across multiple partners): —Capability to retrieve the information. —Accuracy of the information (within and between systems).</td>
</tr>
<tr>
<td></td>
<td>• Different methods for exchanging information (e.g., the use of Electronic Data Interchange, Electronic Product Code Information Services, and other solutions separately).</td>
<td>• Security and access: —Evaluate and document access levels for trading partners.</td>
</tr>
<tr>
<td><strong>Data/Database/System Issues.</strong></td>
<td>• Data quality from beginning to end of the product lifecycle and vice versa.</td>
<td>• System Performance and Effectiveness: —Time to access and use product tracing information once that data is received into a system. —Quality of product tracing information. —Number of breaches to system. —Number of attempts to breach the system that were prevented or minimized.</td>
</tr>
<tr>
<td></td>
<td>• System performance when full or partially loaded with data.</td>
<td>• Data and product flow. —Number of unsuccessful attempts to access data and operational impacts. —Number of system interactions within one, and amongst multiple, trading partners. —Time and resource changes on operations when data and product not moving at same time (e.g., product arrives before data arrives). —Time for location/ownership/status changes to be reflected in the system. —Time of product flow delays and associated costs due to system or data problems.</td>
</tr>
<tr>
<td></td>
<td>• Data format or processes for data transfer: —Use of technical standards for defining data attributes to enable interoperable transfers. —Methods to handle the “master data” (product-specific data) and transaction data separately to minimize “master data” redundancy.</td>
<td>• Data and product flow. —Number of unsuccessful attempts to access data and operational impacts. —Number of system interactions within one, and amongst multiple, trading partners. —Time and resource changes on operations when data and product not moving at same time (e.g., product arrives before data arrives). —Time for location/ownership/status changes to be reflected in the system. —Time of product flow delays and associated costs due to system or data problems.</td>
</tr>
<tr>
<td></td>
<td>• Integration into individual/company data systems.</td>
<td>• Data and product flow. —Number of unsuccessful attempts to access data and operational impacts. —Number of system interactions within one, and amongst multiple, trading partners. —Time and resource changes on operations when data and product not moving at same time (e.g., product arrives before data arrives). —Time for location/ownership/status changes to be reflected in the system. —Time of product flow delays and associated costs due to system or data problems.</td>
</tr>
<tr>
<td></td>
<td>• Control and access to data by trading partners, FDA, or other federal or state officials (data governance).</td>
<td>• Data and product flow. —Number of unsuccessful attempts to access data and operational impacts. —Number of system interactions within one, and amongst multiple, trading partners. —Time and resource changes on operations when data and product not moving at same time (e.g., product arrives before data arrives). —Time for location/ownership/status changes to be reflected in the system. —Time of product flow delays and associated costs due to system or data problems.</td>
</tr>
<tr>
<td></td>
<td>• Ability of the system to record product status (e.g., to indicate expired, illegitimate, in error, quarantined) at all packaging levels.</td>
<td>• Data and product flow. —Number of unsuccessful attempts to access data and operational impacts. —Number of system interactions within one, and amongst multiple, trading partners. —Time and resource changes on operations when data and product not moving at same time (e.g., product arrives before data arrives). —Time for location/ownership/status changes to be reflected in the system. —Time of product flow delays and associated costs due to system or data problems.</td>
</tr>
<tr>
<td><strong>Aggregation/Disaggregation</strong></td>
<td>• Multiple levels of adoption of inference, by different trading partners. Impact of inference gaps, changes or errors in data, particularly downstream when searching or examining the data; how can errors be corrected.</td>
<td>• Number of system and product interactions within one, and amongst multiple, trading partners. —Time required to conduct aggregate/disaggregate operations and transactions. —Accuracy of aggregation data (measure error counts). —Time to gather aggregation/disaggregation data for investigations and notifications. —Time to resolve errors in data.</td>
</tr>
</tbody>
</table>
In addition to the information in table 1, workshop participants and comments submitted to the public docket recommended factors that FDA should take into consideration when establishing pilot projects. The recommended factors include the extent to which the pilot projects:

- Represent the mix of products and levels of packaging in the supply chain
- Include a diverse set of supply chain stakeholders (types and sizes) and transaction types
- Use adaptive design to make the pilot projects more efficient.
- Target known weaknesses in the supply chain
- Can be completed in such a time frame to provide useful information for trading partners
- Evaluate human factors that could present implementation challenges
- Simulate illegitimate products/transactions to test a process or system
- Document costs to implement, use, and maintain piloted solutions

Although the Agency intends to take these factors into consideration when establishing pilot projects, FDA also recognizes that a single pilot project is unlikely to satisfy every factor. Accordingly, requests to establish a pilot project need not satisfy all the factors listed in this document.

C. Instructions for Submitting a Request To Participate in the DSCSA Pilot Project Program

Stakeholders interested in participating in the DSCSA Pilot Project Program may submit a request to participate by email to DSCSAPilotProjects@fda.hhs.gov. For a group of entities that partner to participate in a pilot project, only one submission and one point-of-contact for the proposed pilot project should be provided in the request to participate. Requests to participate may also consider other ideas for a pilot project that are not included in this notice.

D. Submission Content for Requesting To Participate in the DSCSA Pilot Project Program

The following information should be included in the request:

- Contact information for the submitter or point of contact, if different from the submitter (name, mailing address, phone number, email address)
- Names of all partnering entities that would participate in the pilot project (name of company and name of company representative)
- Type(s) of each partnering entity participating in the pilot project (e.g., manufacturer, repackers, wholesale distributor, dispenser, third-party logistics provider, solution provider, trade association, etc.): Partnering entities may include authorized trading partners or other supply chain stakeholders
- Number of employees for each partnering entity to reflect company size
- Proposed start and finish dates of the pilot project
- Commitment to start the pilot project within 4 months of receiving a letter of acceptance from FDA
- Product(s) that will be used in the pilot project
- Location(s) where pilot project will be performed (facility address)
• Description of the proposed pilot project, including, but not limited to, the goals, objectives, processes that will be studied, and evaluation methods

E. Initiation and Duration of Pilot Projects

The selected participants should be ready to start their pilot project within 4 months of receiving a letter of acceptance from FDA into the program. The duration of a pilot project should not exceed 6 months. FDA may consider a pilot project with a later start date or longer duration depending on the proposed goal(s) and objective(s). Each pilot project is expected to be completed within the proposed duration time period. This time period does not include an additional 30 days for completion of a final report (see Section II.G. Reports).

F. Participation in Pilot Projects

Each participant that is selected into the program will be responsible for conducting its pilot project. A group of entities (e.g., members of the pharmaceutical distribution supply chain or other stakeholders, including trade associations) that partners to conduct a pilot project will be considered a single participant for purposes of the DSCSA Pilot Project Program. The participant will be responsible for the funding and resources necessary to conduct the pilot project, and for determining each partner’s role and responsibility in its pilot project.

Prior to launch of a pilot project, FDA intends to hold a design strategy meeting with the selected pilot participant(s) to review the goal(s) and objective(s) for the pilot project and discuss the project plans and other pertinent details. FDA also expects pilot project participants to submit reports on the progress of their pilot projects to FDA (see Section II.G. Reports). Participants should evaluate their pilot projects using the evaluation methods they identified during the pilot project design process.

G. Reports

Each pilot project is expected to be completed within the proposed duration time period, and FDA asks that all participants submit periodic progress reports to FDA while the pilot project is being conducted, in addition to submitting a final report after completing the pilot project. These reports will provide insight into the system work process needed to comply with certain DSCSA requirements for enhanced drug distribution security.

1. Progress Report(s)

Each pilot project program participant is expected to provide reports on the progress of its pilot project to FDA. The progress reports are intended to capture the ongoing work during the pilot project, including but not limited to, status or results, changes, challenges, and/or lessons learned. FDA will work with participants to develop an appropriate schedule for the submission of progress reports based on the design and duration of the pilot project. Because the duration of a pilot project should not exceed 6 months, the frequency of progress reports will vary based on the length of the individual pilot project. Pilot projects of relatively shorter duration may result in shorter time intervals between progress reports. For example, FDA may ask for monthly progress reports for a 6-month pilot project, however for a 1-month pilot project, FDA may ask for weekly progress reports.

2. Final Report

Within 30 to 45 business days of completing a pilot project, each participant is expected to provide a final report to FDA that captures the description, objectives, methods, evaluation, costs and key findings, and lessons learned from the project. Timely completion of pilot projects and the final report will support FDA’s DSCSA implementation, including the statutory requirements under section 582(j) of the FD&C Act to consider information from pilot projects in the development of guidelines for unit-level tracing and standards for the interoperable data exchange in section 582(h)(3) and (4) of the FD&C Act. FDA may also request that the participants meet with the Agency upon the completion of their pilot project or the final report.

H. Final DSCSA Pilot Project Program Report

To ensure that all supply chain members benefit from the information generated by the DSCSA Pilot Project Program, FDA intends to make the following information about each pilot project of the program available to the public in a final program report: (1) The names and industry sector(s) of the pilot project participant(s); (2) the pilot project’s objectives and evaluation methods; (3) the duration of the pilot project; and (4) the key findings and lessons learned from the pilot project. FDA intends to post the information related to the DSCSA Pilot Project Program and the final program report on FDA’s website.

I. Recordkeeping

Any records generated by a participant while conducting a pilot project should be maintained in accordance with the participant’s normal recordkeeping practices. For pilot projects that involve partnering entities, the partnering entities should decide who is responsible for the records generated in the course of conducting the pilot project. FDA recommends that participants maintain the progress reports and final report for its pilot project for at least 1 year after completion of the pilot project.

III. Paperwork Reduction Act of 1995

This notice contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collection of information in this notice was approved under OMB control number 0910–0859.


Lowell J. Schiller,
Acting Associate Commissioner for Policy.

[FR Doc. 2019–01561 Filed 2–7–19; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Request for Information (RFI): Improving Efficiency, Effectiveness, Coordination, and Accountability of HIV and Viral Hepatitis Prevention, Care, and Treatment Programs

AGENCY: Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: Both the National HIV/AIDS Strategy (NHAS) and the National Viral Hepatitis Action Plan (NVHAP) expire in 2020. The Department of Health and Human Services (HHS) Office of HIV/AIDS and Infectious Disease Policy (OHAIDP), in collaboration with federal partners, is leading development of the next iterations of these two separate and distinct national strategies. To help inform the next iterations of the NHAS and NVHAP, HHS seeks input from external stakeholders for improving efficiency, effectiveness, coordination, and accountability of HIV and viral hepatitis prevention, care, treatment, and cure policies, services, and programs.

DATES: To be assured consideration, comments must be received at the